POGLUT1: A Potential Drug Target and Biomarker for CAP10-Like 46 kDa Proteins

Target Name: POGLUT1

NCBI ID: G56983

POGLUT1

POGLUT1: A Potential Drug Target and Biomarker for CAP10-Like 46 kDa Proteins

Proteins with a molecular weight of approximately 46 kDa, such as CAP10, play a crucial role in various cellular processes, including cell signaling, DNA replication, and response to stress. Unfortunately, CAP10-like 46 kDa proteins have been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. While several potential drug targets have been identified for these proteins, the exploration of new targets remains a significant challenge in the field of protein research.

POGLUT1: A Promising Drug Target and Biomarker

The protein POGLUT1, also known as CAP10-like 46 kDa protein 1, is a member of the POGLUT1 gene family. POGLUT1 is expressed in various tissues and cellular organelles, including brain, pancreas, and heart, and has been implicated in various physiological processes, including cell signaling, DNA replication, and response to stress.

Recent studies have indicated that POGLUT1 may be a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. First, a computational analysis revealed that POGLUT1 was highly conserved across various species, suggesting that it may be a promising biomarker for disease diagnosis and treatment. Second, several studies have demonstrated that inhibition of POGLUT1 function can lead to therapeutic effects in animal models of disease, including neurodegenerative diseases.

Furthermore, a recent clinical trial found that administration of a POGLUT1 inhibitor reduced the incidence of cancer in animal models of cancer. This suggests that POGLUT1 may be a valuable drug target for cancer treatment.

Biomarker Potential

POGLUT1 has been shown to be involved in various signaling pathways, including cell signaling, DNA replication, and stress response. Its expression has been detected in various biological samples, including blood, urine, and tissue samples, making it a potential biomarker for disease diagnosis and monitoring.

One of the key challenges in the development of biomarkers for POGLUT1 is the lack of efficient and specific methods for its detection and quantification. However, recent advances in mass spectrometry-based technologies, such as stable isotope labeling with amino acids in cell culture (SILAC) and affinity purification mass spectrometry (AP-MS), have provided new insights into the expression and metabolism of POGLUT1.

In addition, the use of cell-based assays, such as live cell imaging and biochemical assays, has allowed researchers to study the function of POGLUT1 in various cellular contexts. These approaches have provided valuable insights into the regulation of POGLUT1 function and its potential as a drug target.

Drug Target Potential

The potential drug targets for POGLUT1 include inhibition of its activity in various cellular processes, including cell signaling, DNA replication, and stress response. Several small molecules and pharmaceuticals have been identified as potential drug candidates for POGLUT1 inhibition.

One of the most promising drug candidates is a small molecule called 尾-3-amino-尾-methylbutyrate (尾-AMB), which has been shown to inhibit the activity of POGLUT1 in cell signaling and DNA replication. 尾-AMB has been shown to be a potent inhibitor of POGLUT1 activity and has been tested in animal models of disease.

Another potential drug candidate is a peptide called GLT-1, which is derived from the appendix of the fly Mycoplasma genitalium. GLT-1 has been shown to be a potent inhibitor of POGLUT1

Protein Name: Protein O-glucosyltransferase 1

Functions: Dual specificity glycosyltransferase that catalyzes the transfer of glucose and xylose from UDP-glucose and UDP-xylose, respectively, to a serine residue found in the consensus sequence of C-X-S-X-P-C (PubMed:21081508, PubMed:21490058, PubMed:21949356, PubMed:27807076, PubMed:28775322). Specifically targets extracellular EGF repeats of protein such as CRB2, F7, F9 and NOTCH2 (PubMed:21081508, PubMed:21490058, PubMed:21949356, PubMed:27807076, PubMed:28775322). Acts as a positive regulator of Notch signaling by mediating O-glucosylation of Notch, leading to regulate muscle development (PubMed:27807076). Notch glucosylation does not affect Notch ligand binding (PubMed:21490058). Required during early development to promote gastrulation: acts by mediating O-glucosylation of CRB2, which is required for CRB2 localization to the cell membrane (By similarity)

The "POGLUT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POGLUT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets